doc. RNDr. Pavel Souček, CSc. ****************************************************************************************** * ******************************************************************************************
Department of Toxicogenomics Centre for Toxicology and Health Safety State Institute of Health Šrobárova 48, Praha 10 – 100 42 tel: +420 267 082 711, e-mail: pavel.soucek(zavinac)szu.cz [ MAIL "pavel.soucek(zavinac)sz http://www.szu.cz/oddeleni-toxikogenomiky [ URL "http://www.szu.cz/oddeleni-toxikogenomiky Advisors: Doc. RNDr. Pavel Souček, CSc. RNDr. Radka Václavíková, PhD Mgr. Viktor Hlaváč, PhD *========================================================================================= * Description of scientific activity *========================================================================================= The Department of Toxicogenomics of the National Cancer Institute deals with complex resea influence of molecular factors (genomics, epigenomics, transcriptomics, proteomics and met the development of cancer and the course of oncological diseases. One of our goals is to u development of cancer and use its characteristics to define therapeutically relevant tools or slow its progression and ultimately contribute to the development of targeted drugs and specifically target cancer cells. We are looking for clinically interesting prognostic and biomarkers in the tissues and blood of cancer patients to assess the risk of disease recur the response of cancer patients to therapy (precision oncology). Using model cancer cell l investigating the mechanisms of action of known and experimental anticancer drugs and look enhance their therapeutic effect or reduce tumor resistance. Furthermore, we are studying have not yet been included in clinical trials and we are developing in vivo models of canc patient xenografts. Our excellence is based on more than 20 years of experience in this fi a number of projects including international projects (see selected projects), published s (see selected publications) and broad international collaborations (see selected collabora *========================================================================================= * Selected publications *========================================================================================= Kloudová-Spálenková A, Holý P, Souček P. Oxysterols in Cancer Management: From Therapy to J Pharmacol. 2021;178:3235–3247. doi: 10.1111/bph.15273. Hlaváč V, Holý P, Souček P. Pharmacogenomics to Predict Tumor Therapy Response: A Focus on Cassette Transporters and Cytochromes P450. J Pers Med. 2020;10(3):E108. doi:10.3390/jpm10 Bleach R, Madden SF, Hawley J, Charmsaz S, Selli C, Sheehan KM, Young LS, Sims AH, Souček McIlroy M. Steroid ligands, the forgotten triggers of nuclear receptor action; implication resistance to endocrine therapy. Clin Cancer Res. 2021; 27(14):3980-9. doi: 10.1158/1078-0 *========================================================================================= * Selected or ongoing grants/clinical studies *========================================================================================= AZV č. NV19-08-00113: Feasibility study of next-generation sequencing for individualized t patients with solid tumors; GAČR č. 21-14082S: The role of Notch signaling pathway in the mechanism of action of new t derivatives; INTER-EXCELLENCE č. LTAUSA19: Study of the relationship between structure and function of derivatives in combating cancer cell resistance. *========================================================================================= * PhD Students *========================================================================================= Number of current PhD students: 10 Number of defended students with year of defense: 10 (1x 2020, 3x 2017, 2x 2013, 1x 2012, a 1x 2004)